Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has given ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback